Quetiapine
- Generic Name
- Quetiapine
- Brand Names
- Seroquel
- Drug Type
- Small Molecule
- Chemical Formula
- C21H25N3O2S
- CAS Number
- 111974-69-7
- Unique Ingredient Identifier
- BGL0JSY5SI
- Background
Initially approved by the FDA in 1997, quetiapine is a second-generation atypical antipsychotic used in schizophrenia, major depression, and bipolar disorder. Quetiapine demonstrates a high level of therapeutic efficacy and low risk of adverse effects during long-term treatment. It is well-tolerated and a suitable option for some patients with high sensitivi...
- Indication
Quetiapine is used in the symptomatic treatment of schizophrenia. In addition, it may be used for the management of acute manic or mixed episodes in patients with bipolar I disorder, as a monotherapy or combined with other drugs. It may be used to manage depressive episodes in bipolar disorder. In addition to the above indications, quetiapine is used in comb...
- Associated Conditions
- Bipolar 1 Disorder, Depressive Episodes, Generalized Anxiety Disorder, Major Depressive Disorder (MDD), Mixed manic depressive episode, Post Traumatic Stress Disorder (PTSD), Psychosis, Schizophrenia, Acute Manic episode
- Associated Therapies
- -
Quetiapine Versus Trazadone in Women With Postpartum Depression
- Conditions
- Interventions
- First Posted Date
- 2024-08-09
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Lawson Health Research Institute
- Target Recruit Count
- 50
- Registration Number
- NCT06546358
- Locations
- 🇨🇦
Parkwood Institute, London, Ontario, Canada
Sequential Multiple Assignment Randomized Trial for Bipolar Depression
- Conditions
- Interventions
- First Posted Date
- 2024-05-30
- Last Posted Date
- 2024-05-30
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 2726
- Registration Number
- NCT06433635
- Locations
- 🇺🇸
McLean Hospital, Belmont, Massachusetts, United States
🇺🇸John Hopkins, Baltimore, Maryland, United States
🇺🇸University of Pennsylvania, Philadelphia, Pennsylvania, United States
Synergistic Effect of Vitamin E & D in Reducing Risk of Effects Associated With Atypical Anti-psychotics
- First Posted Date
- 2024-01-11
- Last Posted Date
- 2024-01-11
- Lead Sponsor
- Dr Rabia Arshad
- Target Recruit Count
- 140
- Registration Number
- NCT06200584
- Locations
- 🇵🇰
Jinnah Post Graduate Medical Centre, Karachi, Sindh, Pakistan
Efficacy of Melatonin, Low-dose Quetiapine, or Placebo in Patients with Psychiatric Disorders and Comorbid Insomnia
- Conditions
- Interventions
- First Posted Date
- 2023-10-02
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Lone Baandrup
- Target Recruit Count
- 255
- Registration Number
- NCT06062953
- Locations
- 🇩🇰
Mental Health Center Copenhagen, Copenhagen NV, Denmark
The Effect of a Six Week Intensified Pharmacological Treatment for Bipolar Depression Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.
- Conditions
- Interventions
- First Posted Date
- 2023-08-03
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Dr. Inge Winter
- Target Recruit Count
- 418
- Registration Number
- NCT05973786
- Locations
- 🇦🇹
Medical University Innsbruck, Innsbruck, Austria
🇩🇪Universitätsklinik für Psychiatrie und Psychotherapie Bielefeld, Bielefeld, Germany
🇩🇪University Hospital Frankfurt am Main - Goethe University, Frankfurt am Main, Germany
Using 18F-FPEB PET to Identify mGLUR5 Availability in Affective Disorders
- Conditions
- Interventions
- First Posted Date
- 2023-05-03
- Last Posted Date
- 2023-08-14
- Lead Sponsor
- Central South University
- Target Recruit Count
- 59
- Registration Number
- NCT05840861
- Locations
- 🇨🇳
Mental Health Institute & Faculty of Psychiatry of The Second Xiangya Hospital, Central South University, Changsha, Hunan, China
Quetiapine as Prophylaxis for Delirium in CABG
- First Posted Date
- 2023-04-06
- Last Posted Date
- 2023-04-06
- Lead Sponsor
- Ain Shams University
- Target Recruit Count
- 60
- Registration Number
- NCT05801289
- Locations
- 🇪🇬
Ain shams university hospitals, Cairo, Egypt
Quetiapine in Prevention of Delirium
- First Posted Date
- 2023-03-31
- Last Posted Date
- 2023-07-10
- Lead Sponsor
- Ain Shams University
- Target Recruit Count
- 90
- Registration Number
- NCT05793632
- Locations
- 🇪🇬
Ain Shams University, Cairo, Egypt
Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure
- Conditions
- Interventions
- First Posted Date
- 2022-11-02
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Dr. Inge Winter
- Target Recruit Count
- 1254
- Registration Number
- NCT05603104
- Locations
- 🇮🇱
Sheba Medical Center, Ramat Gan, Israel
Comparing Antipsychotic Medications in LBD Over Time
- Conditions
- Interventions
- First Posted Date
- 2022-10-21
- Last Posted Date
- 2024-10-30
- Target Recruit Count
- 94
- Registration Number
- NCT05590637
- Locations
- 🇺🇸
University Health System, San Antonio, Texas, United States
🇺🇸UT Health Science Center - San Antonio, San Antonio, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.